Why Is Genus plc (LSE:GNS) Down on 12 Nov 2026?

Genus plc shares fell 4.18% to around 2,290.0p on 12 Nov 2026, a decline of 100.00p, based on market data. The move comes after the company's FY26 results published in September 2026, which reported higher adjusted profit and the launch of a £60 million share buyback.

Genus is a leading animal genetics business, supplying porcine genetics through PIC and bovine genetics through ABS. It is also developing the PRRS-resistant pig, a gene-edited innovation with potential benefits for animal health and food production.

This article reviews the latest results and the factors that may shape the next stage for LSE:GNS.

Key Highlights

For FY26, Genus reported adjusted profit before tax of £100.2 million, up 35%, and adjusted EPS of 110.3p, also up 35%.

The group announced a full-year Dividend of 35.2p per share, up 10%, and a £60 million share buyback expected to complete during FY27.

Free Cash Flow rose 52% to £62.0 million, and Leverage fell to 0.4x following the sale of a 51% interest in PIC China.

About Genus plc

Genus plc is a British-based global company that improves the productivity and health of farmed animals through advanced genetics.

PIC supplies porcine genetics to producers around the world, while ABS provides bovine genetics, including sexed semen products used by dairy and beef farmers.

Both divisions earn Revenue through royalties and product sales linked to the performance of their genetics.

Its focus on animal genetics and health outcomes gives LSE:GNS a science-led profile within the healthcare sector.

Key Reasons Behind the 12 Nov 2026 Move

The 12 Nov 2026 decline of 4.18% came when the company's most recent regulatory notices were routine share buyback transactions rather than new trading information.

Share prices can respond to broader sector sentiment, movements in the wider market and changes in investor positioning, particularly after a period of Earnings growth.

The company has said that FY27 earnings are expected to be weighted towards the second half, so the next major earnings event is still some way off.

The share buyback programme continues, with regular transaction notices published by the company.

FY26 Financial Performance

Group revenue was £658.1 million, down 2% as reported and flat at constant currency excluding PIC China.

Adjusted operating profit rose 17% to £94.8 million, or 25% to £116.0 million including joint ventures.

Statutory profit before tax was £310.5 million, including a £204.1 million gain on the sale of a 51% interest in PIC China.

Net proceeds from the PIC China transaction were approximately £98 million, supporting the reduction in leverage to 0.4x from 1.5x.

PIC and ABS Performance

PIC increased total Volume by 12% including joint ventures. Adjusted Royalty revenue was £196.9 million, up 5%, and adjusted operating profit including joint ventures rose 17% to £130.8 million.

ABS volume was up 1%, with sexed volume up 2%, while adjusted operating profit including joint ventures was £22.9 million.

ABS has benefited from the Value Acceleration Program, although lower global dairy prices and a more cautious customer backdrop were noted during the year.

PRRS-Resistant Pig Progress

Genus has received approvals or favourable determinations for the PRRS-resistant pig in Argentina, Canada, Uruguay and Peru.

The company has begun commercialisation in selected Latin American markets.

PRRS is a widespread disease in pig production, and a gene-edited pig that resists the virus may offer benefits for animal welfare and producer productivity.

Further regulatory milestones in major pork markets remain an important area to follow for LSE:GNS.

Capital Returns and Outlook

The full-year dividend of 35.2p includes a final dividend of 24.0p.

A £60 million share buyback is expected to complete during FY27.

For FY27, the company expects adjusted profit before tax at constant currency to be in line with market expectations and moderately above the normalised FY26 figure of £90.3 million, with moderate adjusted operating profit growth from both PIC and ABS.

Key Growth Catalysts

Regulatory progress and commercial roll-out of the PRRS-resistant pig can broaden LSE:GNS's long-term opportunity.

Growth in PIC volumes, including joint ventures, supports royalty revenue.

ABS's Value Acceleration Program aims to improve efficiency and customer offering.

The porcine joint venture with Beijing Capital Agribusiness, formed in January 2026, provides a route to the Chinese market.

An improved Balance Sheet allows continued Investment and Shareholder returns.

Key Considerations

Regulatory decisions on gene-edited animals vary by country and can affect timing.

Global dairy prices and customer Demand influence ABS performance.

Currency movements affect reported results given the group's international operations.

Earnings are expected to be weighted towards the second half of FY27, which may lead to uneven progress between reporting periods.

Share Price Context

Based on market data, LSE:GNS traded at around 2,290.0p on 12 Nov 2026, down 100.00p.

The FY26 figures, including adjusted EPS of 110.3p and a dividend of 35.2p per share, provide context for how the market views the shares.

Longer-term direction will depend on PIC and ABS growth, progress with PRRS-resistant pigs and capital returns.

What to Watch Next

Further regulatory decisions on the PRRS-resistant pig, particularly in major pork-producing countries.

Progress with the £60 million buyback.

Interim results for FY27, where earnings weighting will be a point of interest.

Updates on the Chinese porcine joint venture.

Conclusion

Genus plc shares fell 4.18% to around 2,290.0p on 12 Nov 2026, following a period of routine buyback activity.

FY26 results showed adjusted profit before tax of £100.2 million, a full-year dividend of 35.2p and a £60 million buyback.

PIC volume growth, ABS execution, the PRRS-resistant pig and capital returns are the key themes to follow.